We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,091.00 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,347 | 22:05:20 |
From Jul 2021 to Jul 2024
By Maria Armental
Regeneron Pharmaceuticals Inc.'s board has approved up to $3 billion more in stock repurchases, the company said Friday.
The authorization has no time limit, the company said. As of Nov. 12, $1.8 million remained available for share repurchases under a prior $1.5 billion share repurchase program authorized in January.
"With the strength of our balance sheet and our business, we see this as an opportunity to continue to invest in Regeneron," Chief Financial Officer Robert E. Landry said in a statement.
Through Sept. 30, Regeneron reported a profit of $5.85 billion on $11.12 billion in revenue, up from $2.36 billion on $6.07 billion in revenue for the comparable nine-month period a year earlier.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
November 12, 2021 16:38 ET (21:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
